  Passive surveillance data had signaled the possibility of gastrointestinal adverse events occurring after the administration of high-dose inactivated influenza<disease> vaccine ( IIV-HD). However , in a large , prospective randomized clinical trial , rates of serious gastrointestinal events were no greater among IIV-HD recipients than among those who received a standard-dose influenza<disease> vaccine.